First human test of new hepatitis d drug begins
NCT ID NCT06740474
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and how the body processes a new drug called ABI-6250 in 40 healthy adults. Participants received either the drug or a placebo, and researchers measured side effects and drug levels in the blood. The goal was to gather safety information before testing the drug in people with hepatitis D.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Zealand Clinical Research
Auckland, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients
- Gum disease and hepatitis: a hidden connection revealed?
- Scientists track immune cells in hepatitis d patients on new drug
- Experimental hepatitis b drug shows promise in early trial
- New drug shows promise against rare liver infection
- Tiny study hopes antiviral drug eases dangerous liver pressure